Skip to main content

CDx Diagnostics to Unveil New Data Demonstrating a Significant Advance in the Prevention of the Most Rapidly Growing Cancer in the U.S.

SUFFERN, NY–(Marketwired – May 17, 2016) –  CDx Diagnostics today announced that results from a multi-center, prospective, randomized clinical trial demonstrating that WATS3D (Wide Area Transepithelial Sampling with 3D Tissue Analysis) sharply increases the detection of esophageal dysplasia (precancer), will be presented at Digestive Disease Week® 2016 (DDW), taking place from May 21-24 in San Diego, Calif

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino